Home Tags DESTINY-PanTumor02

Tag: DESTINY-PanTumor02

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

Trastuzumab Deruxtecan Shows Clinically Meaningful Survival Across Multiple HER2 Expressing...

Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial (ClinicalTrials.gov Identifier: NCT04482309) * confirms that trastuzumab deruxtecan ([fam-trastuzumab deruxtecan-nxki in the U.S. only] Enhertu®; Daiichi Sankyo and AstraZeneca) continues to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple human epidermal growth factor receptor 2 (HER2) expressing advanced solid tumors.

ESMO 2023: ADCs Taking Center Stage

During the annual ESMO 2023 Congress, organized by the European Society for Medical Oncology, held October 20 - 24, 2023 in Madrid, Spain, antibody-drug conjugates or ADCs took center stage, with presentations demonstrating the potential these ADCs show in the rapidly changing treatment landscape for various cancers.

X